Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Up 5.53%
As of Tuesday, October 27, Dyne Therapeutics, Inc.’s DYN share price has surged by 5.53%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Up 5.52%
As of Tuesday, October 20, Dyne Therapeutics, Inc.’s DYN share price has surged by 5.52%, which has investors questioning if this is right time to sell.Michael Rose
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Up 5.61%
As of Monday, October 19, Dyne Therapeutics, Inc.’s DYN share price has surged by 5.61%, which has investors questioning if this is right time to sell.Michael Rose
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.17%
As of Friday, October 16, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.26%
As of Friday, September 18, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | DYN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,374.5 | $219.9 | 62% |
|
| Shares Out (Mil) | 181.8 | 54.1 | 74% |
|
| Institutional Ownership | 99.7% | 92.9% | 92% |
|
| Float (Mil) | 186.2 | 41.4 | 72% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 2,473 | 522 | 83% |
|
| Price Change (52-week) |
(13.5%) | 44.7% | 39% |
|
| Growth | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (49.7%) | (10.1%) | 7% |
|
| EPS (5yr) | 3.4% | 15.8% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (29.2%) | (15.7%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 15 | 13 | |
| Current EPS | ($0.907) | ($3.528) | ($3.311) | |
| Month Ago EPS | ($0.891) | ($3.549) | ($3.335) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.871) | ($3.548) | ($3.263) | |
| Year/Year Chg | (14.8%) | 1.6% | (27.2%) | |
| Financials | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($605) | ($44) | 2% |
|
| EPS (TTM) | ($3.665) | ($1.500) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($565) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $342 | $0 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $213 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | $2,572 | $166 | 52% |
|
| Valuation | DYN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.64 | 2.06 | 74% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | DYN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (57.6%) | (47.5%) | 10% |
|
| ROE | (74.6%) | (52.7%) | 11% |
|
| Liabilities to Assets | 24.6% | 29.6% | 17% |
|
| F-Score | 1 | 3 | 1% |
|
Dyne Therapeutics, Inc. did not pass any screens on 11/6/2026.
